2005 Annual Meeting | Non-Alzheimer's Dementia

Date Friday 04/15/05

Time 09:00 AM - 12:45 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type AM Half-Day Course

Director(s) Jeffrey L. Cummings, MD, FAAN

Topic(s) Aging/Dementia/Degenerative Disease

Learning Objectives Upon completion:
Participants should know the major clinical and imaging features of the major non-Alzheimer dementias and be able to recognize these disorders clinically.

The American Board of Psychiatry and Neurology has reviewed Non-Alzheimer's Dementia and has approved this product as part of a comprehensive lifelong learning program, which is mandated by the ABMS as a necessary component of maintenance of certification.

CME Available No CME available

Program Level Advanced

Recommended Audience Practitioner, Fellow, Academician, Resident

Event Timeline
09:00 AM - 09:50 AM		Vascular Dementia Charles S. DeCarli, MD, FAAN
09:50 AM - 10:40 AM		Dementia with Lewy Bodies Daniel Kaufer, MD, FAAN
10:40 AM - 11:05 AM		Break
11:05 AM - 11:55 AM		Frontotemporal Dementia Bruce L. Miller, MD, FAAN
11:55 AM - 12:45 PM		Differential Diagnosis of Dementing Disorders Jeffrey L. Cummings, MD, FAAN

Faculty Disclosures
Jeffrey L. Cummings, MD, FAAN	Dr. Cummings has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acadia, Actinogen, Acumen, AlphaCognition, ALZpath, Aprinoia, AriBio, Artery, Biogen, Biohaven, BioVie, BioXcel, Bristol-Myers Squib, Cassava, Cerecin, Diadem, Eisai, GAP Foundation, GemVax, Janssen, Jocasta, Karuna, Lighthouse, Lilly, Lundbeck, LSP/eqt, Mangrove Therapeutics, Merck, NervGen, New Amsterdam, Novo Nordisk, Oligomerix, ONO, Optoceutics, Otsuka, Oxford Brain Diagnostics, Prothena, ReMYND, Roche, Sage Therapeutics, Signant Health, Simcere, sinaptica, Suven, TrueBinding, Vaxxinity, and Wren pharmaceutical, assessment, and investment companies. Dr. Cummings has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Acadia, Biogen, Genentech, Grifols, Janssen, Karuna, Otsuka, reMYND, Roche, Signant Health. Dr. Cummings has stock in Artery, Vaxxinity, Behrens, Alzheon, MedAvante-Prophase, and Acumen. Dr. Cummings has received research support from NIH. Dr. Cummings has received research support from NIGMS. Dr. Cummings has received intellectual property interests from a discovery or technology relating to health care.
Bruce L. Miller, MD, FAAN	Dr. Miller has nothing to disclose.
Daniel Kaufer, MD, FAAN	No disclosure on file
Charles S. DeCarli, MD, FAAN	Dr. DeCarli has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Dr. DeCarli has received research support from NIH.

��ɫ��

��ɫ��